本研究旨在从中国医疗保健系统的角度系统分析舒格利单抗和化疗联合治疗治疗晚期食管鳞癌的成本效益。开发了一种晚期食管鳞癌患者模拟分区生存方法模型来模拟接受化疗的患者的疾病进展。舒格利单抗联合化疗与单独化疗的比较。为了确保准确性和精确性，从综合临床试验和可靠的经济数据库中收集临床数据、治疗成本和效用价值。成本效益分析是通过评估与既定支付意愿门槛相关的增量成本效益比来进行的。进行单因素和概率敏感性分析以评估模型的稳健性。使用舒格利单抗的患者组的累计支出为 41734.87 美元，而安慰剂组的总费用为 22926.25 美元。通过评估 ICER（量化每获得 QALY 所产生的额外成本），确定每 QALY 的价值为 61066.96 美元。值得注意的是，该 ICER 值超过了中国预定的 WTP 阈值，即每 QALY 39,855.79 美元。敏感性分析表明，结果对舒格利单抗的成本、无进展生存期和效用值敏感。这些波动并没有导致研究结果的逆转。在中国，舒格利单抗联合化疗治疗食管鳞癌目前不被认为是一种具有成本效益的治疗方法。然而，建议进一步降低价格可能会促进实现成本效益的潜力。版权所有 © 2024 Cai、Fang 和 Cheng。

This study aims to systematically analyze the cost-effectiveness of the combination therapy comprising sugemalimab and chemotherapy in the management of advanced ESCC from the Chinese healthcare system perspective.An advanced ESCC patient simulation partitioned survival approach model was developed to mimic the disease progression of patients undergoing treatment with sugemalimab in combination with chemotherapy versus chemotherapy alone. To ensure accuracy and precision, clinical data, treatment costs, and utility values were collected from comprehensive clinical trials and reliable economic databases. The cost-effectiveness analysis was conducted by assessing the incremental cost-effectiveness ratio in relation to the established willingness-to-pay threshold. One-way and probabilistic sensitivity analyses were performed to assess the robustness of the model.The cumulative expenditure for the group of patients administered with sugemalimab amounted to US$ 41734.87, whereas the placebo group was associated with a total cost of US$ 22926.25. By evaluating the ICER, which quantifies the additional cost incurred per QALY gained, a value of US$ 61066.96 per QALY was determined. It is imperative to note that this ICER value surpasses the predetermined threshold for WTP in China, set at US$ 39,855.79 per QALY. Sensitivity analyses demonstrated that the results were sensitive to the cost of sugemalimab, progression-free survival, and utility values. These fluctuations did not result in a reversal of the study findings.The combination of sugemalimab with chemotherapy for the treatment of ESCC in China is currently not considered a cost-effective therapeutic approach. However, it is suggested that additional reductions in price may facilitate the potential for achieving cost-effectiveness.Copyright © 2024 Cai, Fang and Zheng.